

**DESCRIPTION**

|                           |   |
|---------------------------|---|
| <b>Species Reactivity</b> | Human   |
| <b>Specificity</b>        | Detects recombinant human TIM-3 in direct ELISAs and Western blots.   |
| <b>Source</b>             | Monoclonal Rat IgG <sub>1</sub> Clone # 344801  |
| <b>Purification</b>       | Protein A or G purified from hybridoma culture supernatant  |
| <b>Immunogen</b>          | Mouse myeloma cell line NS0-derived recombinant human TIM-3<br>Met1-Arg200<br>Accession # Q8TDQ0  |
| <b>Endotoxin Level</b>    | <0.10 EU per 1 µg of the antibody by the LAL method.  |
| <b>Formulation</b>        | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.<br>*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS. |

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

|                         |   |
|-------------------------|---|
| <b>Agonist Activity</b> | Rat Anti-Human TIM-3 Monoclonal Antibody (Catalog # MAB23651) exhibits agonist activity by inhibition of NK cell mediated toxicity. Ndhlovu, L. <i>et al.</i> (2012) <i>Blood</i> <b>119</b> :3734. |
|-------------------------|---|

**PREPARATION AND STORAGE**

|                                |  |
|--------------------------------|--|
| <b>Reconstitution</b>          | Reconstitute at 0.5 mg/mL in sterile PBS.  |
| <b>Shipping</b>                | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.<br>*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C   |
| <b>Stability &amp; Storage</b> | <b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul> |

**BACKGROUND**

TIM-3 (T cell immunoglobulin and mucin domain-3) is a 60 kDa member of the TIM family of immune regulating molecules. TIMs are type I transmembrane glycoproteins with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk (1-3). There are three TIM genes in human and eight in mouse. Mature human TIM-3 consists of a 181 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 78 aa cytoplasmic tail (4). An alternately spliced isoform is truncated following a short substitution after the Ig-like domain. Within the ECD, human TIM-3 shares 58% aa sequence identity with mouse and rat TIM-3. TIM-3 is expressed on the surface of effector T cells (CD4<sup>+</sup> Th1 and CD8<sup>+</sup> Tc1) but not on helper T cells (CD4<sup>+</sup> Th2 and CD8<sup>+</sup> Tc2) (4, 5). NK cells appear to transcribe the highest amounts of Tim-3 among lymphocytes, and when Tim-3 was cross-linked with antibodies it suppressed NK cell-mediated cytotoxicity (6). In chronic inflammation, autoimmune disorders, and some cancers, TIM-3 is upregulated on several other hematopoietic cell types. It also occurs on hippocampal neurons (7-10). The Ig domain of TIM-3 interacts with a ligand on resting but not activated Th1 and Th2 cells (5, 11). The glycosylated Ig domain of TIM-3 binds cell-associated galectin-9. This induces TIM-3 Tyr phosphorylation and pro-apoptotic signaling (8, 12). TIM-3 functions as a negative regulator of Th1 cell activity. Its blockade results in increased IFN-γ production, Th1 cell proliferation and cytotoxicity (5, 10, 11), and regulatory T cell development (5). TIM-3 inhibits the antitumor efficacy of DNA vaccines and chemotherapy by binding to the damage-associated molecular pattern molecule, HMGB1 (13).

**References:**

1. Anderson, A.C. and D.E. Anderson (2006) *Curr. Opin. Immunol.* **18**:665.
2. Mariat, C. *et al.* (2005) *Phil. Trans. R. Soc. B.* **360**:1681.
3. Meyers, J.H. *et al.* (2005) *Trends Mol. Med.* **11**:362.
4. Monney, L. *et al.* (2002) *Nature* **415**:536.
5. Sanchez-Fueyo, A. *et al.* (2003) *Nat. Immunol.* **4**:1093.
6. Ndhlovu, L. *et al.* (2012) *Blood* **119**:3734.
7. Wiener, Z. *et al.* (2007) *J. Invest. Dermatol.* **127**:906.
8. van de Weyer, P.S. *et al.* (2006) *Biochem. Biophys. Res. Commun.* **351**:571.
9. Gielen, A.W. *et al.* (2005) *J. Neuroimmunol.* **164**:93.
10. Oikawa, T. *et al.* (2006) *J. Immunol.* **177**:4281.
11. Sabatos, C.A. *et al.* (2003) *Nat. Immunol.* **4**:1102.
12. Zhu, C. *et al.* (2005) *Nat. Immunol.* **6**:1245.
13. Chiba, S. *et al.* (2012) *Nat. Immunol.* **13**:832.